BioAdvance News

Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes

By WebmasterMarch 3, 2015November 1st, 2024No Comments

Melior Pharmaceuticals Initiates Phase 2 Study with MLR-1023 for Type 2 Diabetes
Read more here

Previous PostRelmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine
Next PostMerganser Biotech Inc. Raises $28 Million in a Series A Financing to Develop Hepcidin Mimetic Peptides